Skip to content

Trilaciclib

Cosela (trilaciclib) is a small molecule pharmaceutical. Trilaciclib was first approved as Cosela on 2021-02-12. It is known to target cyclin-dependent kinase 4, cyclin-dependent kinase 6, cyclin-dependent kinase 7, cyclin-dependent kinase 9, and cyclin-dependent kinase 2. Cosela's patents are valid until 2034-03-14 (FDA).
Trade Name Cosela
Common Name Trilaciclib
Indication
Drug Class Cyclin dependent kinase inhibitors
Trilaciclib
Get full access now